Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $21.39 $25.74 Friday, 10th May 2024 ARWR stock ended at $22.08. This is 10.68% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 16.93% from a day low at $21.79 to a day high of $25.48.
90 days $21.39 $36.72
52 weeks $20.67 $40.89

Historical Arrowhead Research Corporation prices

Date Open High Low Close Volume
Jan 24, 2023 $32.53 $34.15 $32.23 $33.92 799 619
Jan 23, 2023 $33.66 $33.69 $32.28 $32.70 1 232 614
Jan 20, 2023 $34.48 $34.50 $33.14 $33.76 843 790
Jan 19, 2023 $35.84 $36.13 $33.90 $33.93 907 829
Jan 18, 2023 $37.11 $37.66 $35.64 $35.99 828 000
Jan 17, 2023 $36.81 $37.67 $36.17 $36.91 937 663
Jan 13, 2023 $35.99 $37.95 $35.62 $36.82 1 037 600
Jan 12, 2023 $34.36 $36.17 $33.75 $36.15 938 300
Jan 11, 2023 $33.07 $35.42 $32.47 $34.42 1 657 748
Jan 10, 2023 $30.27 $33.05 $29.84 $33.03 1 850 057
Jan 09, 2023 $30.05 $31.00 $28.52 $30.28 3 497 428
Jan 06, 2023 $37.47 $38.32 $35.58 $37.38 946 000
Jan 05, 2023 $37.50 $38.05 $36.77 $37.09 873 728
Jan 04, 2023 $38.80 $38.96 $37.84 $38.08 1 074 366
Jan 03, 2023 $40.80 $41.03 $36.96 $38.51 1 402 762
Dec 30, 2022 $39.77 $40.62 $39.61 $40.56 787 669
Dec 29, 2022 $38.08 $40.41 $37.59 $40.12 1 047 881
Dec 28, 2022 $38.31 $38.98 $37.18 $37.56 563 198
Dec 27, 2022 $38.51 $39.00 $37.90 $38.12 706 070
Dec 23, 2022 $38.24 $38.78 $37.17 $38.30 776 668
Dec 22, 2022 $36.64 $38.25 $36.34 $38.21 1 239 780
Dec 21, 2022 $33.29 $37.24 $33.05 $37.10 1 719 784
Dec 20, 2022 $31.00 $33.36 $30.98 $32.94 848 655
Dec 19, 2022 $31.79 $31.99 $30.01 $31.07 815 726
Dec 16, 2022 $31.00 $32.10 $30.86 $31.77 2 446 416
Click to get the best stock tips daily for free!

About Arrowhead Research Corporation

Arrowhead Research Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P... ARWR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT